Table S5 from Distinct Spatially Resolved Tumor Microenvironment Trajectories Define Benefit from Ramucirumab plus Pembrolizumab in Refractory PD-L1+ Gastric Cancer

Sung Hee Lim; Minae An; You Jeong Heo; Hyuk Lee; Byung‐Hoon Min; Arnav Mehta; Soomin Ahn; Kyoung‐Mee Kim; Seung Tae Kim; Samuel Jacob Klempner; Jeeyun Lee

doi:10.1158/2326-6066.31238980

Table S5 from Distinct Spatially Resolved Tumor Microenvironment Trajectories Define Benefit from Ramucirumab plus Pembrolizumab in Refractory PD-L1+ Gastric Cancer

2026 Open access

Read full text

Authors: Sung Hee Lim, Minae An, You Jeong Heo, Hyuk Lee, Byung‐Hoon Min, Arnav Mehta, Soomin Ahn, Kyoung‐Mee Kim, Seung Tae Kim, Samuel Jacob Klempner, Jeeyun Lee

DOI: 10.1158/2326-6066.31238980

Cited by: 0

Abstract

Supplemental Table S5: Summary of treatment related adverse events in a phase II trial of ramucirumab with pembrolizumab in refractory PD-L1+ gastric cancer (n = 26).

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Gastric Cancer Management and Outcomes Colorectal Cancer Treatments and Studies

Publication details

Publication date: 3 February 2026